Decrements in Morning and Evening Energy Are Associated With a Higher Symptom Burden in Patients With Gynecologic Cancers Receiving Chemotherapy.
Journal
Cancer nursing
ISSN: 1538-9804
Titre abrégé: Cancer Nurs
Pays: United States
ID NLM: 7805358
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
aheadofprint
Résumé
Decrements in energy are a significant problem associated with chemotherapy. To date, no study examined the variability of energy in patients with gynecologic cancers. To identify distinct morning and evening energy profiles in patients with gynecologic cancers and evaluate for differences in demographic and clinical characteristics, other common symptoms, and quality-of-life (QOL) outcomes. A sample of 232 patients with gynecologic cancers completed questionnaires 6 times over 2 cycles of chemotherapy. Latent profile analysis was used to identify distinct morning and evening energy profiles. Differences in demographic and clinical characteristics, other common symptoms, and QOL outcomes were evaluated using parametric and nonparametric tests. Three distinct morning (ie, high [9.2%], low [63.1%], very low [27.1%]) and 2 distinct evening (moderate [30.6%], very low [69.4%]) energy classes were identified. Clinical risk factors associated with the worst morning energy profiles included lower functional status and a higher comorbidity burden. Less likely to exercise on a regular basis was the only characteristic associated with the worst evening energy profile. For both symptoms, the worst profiles were associated with higher levels of depression and sleep disturbance, lower levels of cognitive function, and poorer QOL. Approximately 70% of patients with gynecologic cancers experienced decrements in morning and evening energy. The study identified modifiable risk factors associated with more decrements in morning and evening energy. Clinicians can use these findings to identify higher-risk patients and develop individualized energy conservation interventions for these vulnerable patients.
Sections du résumé
BACKGROUND
BACKGROUND
Decrements in energy are a significant problem associated with chemotherapy. To date, no study examined the variability of energy in patients with gynecologic cancers.
OBJECTIVE
OBJECTIVE
To identify distinct morning and evening energy profiles in patients with gynecologic cancers and evaluate for differences in demographic and clinical characteristics, other common symptoms, and quality-of-life (QOL) outcomes.
METHODS
METHODS
A sample of 232 patients with gynecologic cancers completed questionnaires 6 times over 2 cycles of chemotherapy. Latent profile analysis was used to identify distinct morning and evening energy profiles. Differences in demographic and clinical characteristics, other common symptoms, and QOL outcomes were evaluated using parametric and nonparametric tests.
RESULTS
RESULTS
Three distinct morning (ie, high [9.2%], low [63.1%], very low [27.1%]) and 2 distinct evening (moderate [30.6%], very low [69.4%]) energy classes were identified. Clinical risk factors associated with the worst morning energy profiles included lower functional status and a higher comorbidity burden. Less likely to exercise on a regular basis was the only characteristic associated with the worst evening energy profile. For both symptoms, the worst profiles were associated with higher levels of depression and sleep disturbance, lower levels of cognitive function, and poorer QOL.
CONCLUSIONS
CONCLUSIONS
Approximately 70% of patients with gynecologic cancers experienced decrements in morning and evening energy. The study identified modifiable risk factors associated with more decrements in morning and evening energy.
IMPLICATIONS FOR PRACTICE
CONCLUSIONS
Clinicians can use these findings to identify higher-risk patients and develop individualized energy conservation interventions for these vulnerable patients.
Identifiants
pubmed: 39485897
doi: 10.1097/NCC.0000000000001420
pii: 00002820-990000000-00299
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Pozzar RA, Hammer MJ, Cooper BA, et al. Symptom clusters in patients with gynecologic cancer receiving chemotherapy. Oncol Nurs Forum. 2021;48(4):441–452.
Woopen H, Sehouli J, Davis A, et al. GCIG-Consensus Guideline for Long-term Survivorship in Gynecologic Cancer: a position paper from the Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Committee. Cancer Treat Rev. 2022;107:102396.
Shirali E, Yarandi F, Ghaemi M, Montazeri A. Quality of life in patients with gynecological cancers: a web-based study. Asian Pac J Cancer Prev. 2020;21(7):1969–1975.
Pozzar RA, Hammer MJ, Cooper BA, et al. Stability of symptom clusters in patients with gynecologic cancer receiving chemotherapy. Cancer Nurs. 2022;45(4):E706–E718.
Nho JH, Reul Kim S, Nam JH. Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy. Eur J Oncol Nurs. 2017;30:8–14.
Huang J, Gu L, Zhang L, Lu X, Zhuang W, Yang Y. Symptom clusters in ovarian cancer patients with chemotherapy after surgery: a longitudinal survey. Cancer Nurs. 2016;39(2):106–116.
Hwang KH, Cho OH, Yoo YS. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. Eur J Oncol Nurs. 2016;21:215–222.
MedlinePlus. Fatigue. https://medlineplus.gov/ency/article/003088.htm. Accessed August 11, 2023.
National Cancer Institute. Dictionary of Cancer Terms. http://www.cancer.gov/publications/dictionaries/cancer-terms/def/fatigue. Accessed August 11, 2023.
Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326–1336.
National Comprehensive Cancer Network. Cancer-related fatigue (version 2.2023). 2023. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1424. Accessed August 11, 2023.
Lerdal A. A concept analysis of energy. Scand J Caring Sci. 1998;12(1):3–10.
Lerdal A. A theoretical extension of the concept of energy through an empirical study. Scand J Caring Sci. 2002;16(2):197–206.
Eshragh J, Dhruva A, Paul SM, et al. Associations between neurotransmitter genes and fatigue and energy levels in women after breast cancer surgery. J Pain Symptom Manage. 2017;53(1):67–84.e67.
Abid H, Kober KM, Smoot B, et al. Common and distinct characteristics associated with trajectories of morning and evening energy in oncology patients receiving chemotherapy. J Pain Symptom Manage. 2017;53(5):887–900.e882.
Aouizerat BE, Dhruva A, Paul SM, Cooper BA, Kober KM, Miaskowski C. Phenotypic and molecular evidence suggests that decrements in morning and evening energy are distinct but related symptoms. J Pain Symptom Manage. 2015;50(5):599–614.e593.
Asakitogum DA, Nutor JJ, Pozzar R, et al. Multifactorial model of energy in patients with cancer. Semin Oncol Nurs. 2024;4(3):151644.
Kober KM, Smoot B, Paul SM, Cooper BA, Levine JD, Miaskowski C. Polymorphisms in cytokine genes are associated with higher levels of fatigue and lower levels of energy in women after breast cancer surgery. J Pain Symptom Manage. 2016;52(5):695–708.e694.
Bischel LE, Ritchie C, Kober KM, et al. Age differences in fatigue, decrements in energy, and sleep disturbance in oncology patients receiving chemotherapy. Eur J Oncol Nurs. 2016;23:115–123.
Dhruva A, Aouizerat BE, Cooper B, et al. Differences in morning and evening fatigue in oncology patients and their family caregivers. Eur J Oncol Nurs. 2013;17(6):841–848.
Lin Y, Bailey DE, Docherty SL, et al. Distinct morning and evening fatigue profiles in gastrointestinal cancer during chemotherapy. BMJ Support Palliat Care. 2023;13(e2):e373–e381.
Weiss SJ, Franck LS, Leutwyler H, et al. Theory of Symptom Management. In: Smith MJ, Liehr PR, eds. Middle Range Theory for Nursing. 5th ed. New York, NY: Springer Publishing; 2023:125–141.
Wright F, D’Eramo Melkus G, Hammer M, et al. Trajectories of evening fatigue in oncology outpatients receiving chemotherapy. J Pain Symptom Manage. 2015;50(2):163–175.
Karnofsky D. Performance Scale. New York: Plenum Press; 1977.
Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–163.
Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423–432.
Extermann M, Bonetti M, Sledge GW, O’Dwyer PJ, Bonomi P, Benson AB 3rd. MAX2—a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004;40(8):1193–1198.
Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res. 1991;36(3):291–298.
Fletcher BS, Paul SM, Dodd MJ, et al. Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer. J Clin Oncol. 2008;26(4):599–605.
Spielberger CG, Gorsuch RL, Suchene R, Vagg PR, Jacobs GA. Manual for the State-Anxiety (Form Y): Self Evaluation Questionnaire. Palo Alto, CA: Consulting Psychologists Press; 1983.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measur. 1977;1(3):385–401.
Lee KA. Self-reported sleep disturbances in employed women. Sleep. 1992;15(6):493–498.
Cimprich B, Visovatti M, Ronis DL. The Attentional Function Index—a self-report cognitive measure. Psychooncology. 2011;20(2):194–202.
Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14(1):70–78.
Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17(2):197–210.
Ware J Jr., Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523–531.
Muthen LK, Muthen BO. Mplus User’s Guide. 8th ed. Muthen & Muthen: Los Angeles, CA; 1998-2020.
Mravec B, Tibensky M, Horvathova L. Stress and cancer. Part I: mechanisms mediating the effect of stressors on cancer. J Neuroimmunol. 2020;346:577311–577311.
Muthén L, Muthén B. Statistical analysis with latent variables. Mplus User’s Guide. 2009;7.
Muthen B, Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics. 1999;55(2):463–469.
Ehrenkranz R, Rosso AL, Sprague BN, et al. Functional correlates of self-reported energy levels in the health, aging and body composition study. Aging Clin Exp Res. 2021;33(10):2787–2795.
Moy S, Kober KM, Viele C, et al. Level of exercise influences the severity of fatigue, energy levels, and sleep disturbance in oncology outpatients receiving chemotherapy. Cancer Nurs. 2022;45(1):3–11.
Ward-Ritacco CL, Adrian AL, O’Connor PJ, et al. Feelings of energy are associated with physical activity and sleep quality, but not adiposity, in middle-aged postmenopausal women. Menopause. 2015;22(3):304–311.
Tian Q, Glynn NW, Ehrenkranz RC, Sprague BN, Rosso AL, Rosano C. Perception of energy and objective measures of physical activity in older adults. J Am Geriatr Soc. 2020;68(8):1876–1878.
Loy B, O’Connor P, Dishman R. The effect of a single bout of exercise on energy and fatigue states: a systematic review and meta-analysis. Fatigue Biomed Health Behav. 2013;1:223–242.
Loy BD, Cameron MH, O’Connor PJ. Perceived fatigue and energy are independent unipolar states: supporting evidence. Med Hypotheses. 2018;113:46–51.
Jewett PI, Teoh D, Petzel S, et al. Cancer-related distress: revisiting the utility of the National Comprehensive Cancer Network distress thermometer problem list in women with gynecologic cancers. JCO Oncol Pract. 2020;16(8):e649–e659.
Mattsson E, Einhorn K, Ljungman L, Sundström-Poromaa I, Stålberg K, Wikman A. Women treated for gynaecological cancer during young adulthood—a mixed-methods study of perceived psychological distress and experiences of support from health care following end-of-treatment. Gynecol Oncol. 2018;149(3):464–469.
Cianci S, Tarascio M, Arcieri M, et al. Post treatment sexual function and quality of life of patients affected by cervical cancer: a systematic review. Medicina (Kaunas). 2023;59(4):704.
Logue CA, Pugh J, Jayson G. Psychosexual morbidity in women with ovarian cancer. Int J Gynecol Cancer. 2020;30(12):1983–1989.
Seib C, Harbeck E, Anderson D, et al. Establishing the sensitivity and specificity of the gynaecological cancer distress screen. Psychooncology. 2024;33(3):e6328.
Goyal D, Gay CL, Lee KA. Patterns of sleep disruption and depressive symptoms in new mothers. J Perinat Neonat Nurs. 2007;21(2):123–129.
Papadakis Z, Stamatis A, Manierre M, Boolani A. Preventive medicine via lifestyle medicine implementation practices should consider individuals’ complex psychosocial profile. Healthcare (Basel). 2022;10(12):2560.
Sprague BN, Zhu X, Ehrenkranz RC, et al. Declining energy predicts incident mobility disability and mortality risk in healthy older adults. J Am Geriatr Soc. 2021;69(11):3134–3141.
Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol. 2012;124(3):404–409.
Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371–383.